|
Microbes
An eternal source of innovative drugs
Refined fermentation process development strategies have geared
up microbes as a sustained source of future drugs. Dr H Sivaramkrishna,
President and Dr Girish Mahajan, Group Head, Anti-infective
Screening & Prokaryote Isolation, Department of Natural
Products, Piramal Life Sciences Limited (PLSL) illustrate
the pre-eminence fo microbes in the pharma industry focusing
on three prominent areas: anti-microbial (anti-bacterial and
anti-fungus), anti-cancer and anti-diabetic drugs.
Study
identifies no side effects of rosiglitazone to cardiac diseases
Clinical trial results of the RECORD (Rosiglitazone Evaluated
for Cardiac Outcomes and Regulation of Glycaemia in Diabetes)
study, presented at the American Diabetes Association (ADA)
meeting 2009, showed that overall rates of cardiovascular
hospitalisation and cardiovascular death were similar in patients
taking rosiglitazone compared to those receiving metformin
and sulfonylurea
|
